Argenx Announces Participation in Important Investor Conferences
Argenx (Euronext & Nasdaq: ARGX) is dedicated to advancing the field of immunology and improving the lives of those facing severe autoimmune diseases. The company has recently revealed that its management team will participate in notable investor conferences taking place this month. This engagement is pivotal for fostering relationships and discussing the company’s innovative approaches to healthcare.
Details of Upcoming Conferences
The first of these significant events is the Guggenheim Inaugural Healthcare Innovation Conference, scheduled for Tuesday, November 12. During this conference, a fireside chat will provide insights into argenx's strategic initiatives and future developments at 2:30 p.m. ET in Boston. This session will allow investors to gain a deeper understanding of the company's vision and the impact of their research.
Following this, argenx will be present at the Jefferies London Healthcare Conference. Management will meet with investors on Wednesday, November 20, and Thursday, November 21. This platform serves as a great opportunity for one-on-one interactions, where the team can showcase their advancements and discuss their portfolio of antibody-based medicines.
Access to Live Webcast
For those interested in the Guggenheim conference's fireside chat, a live webcast will be available on the Investors section of the argenx website. This feature ensures that even those unable to attend in person can still participate and learn more about argenx's initiatives. Moreover, a replay of this invaluable session will be accessible for a limited time thereafter.
About Argenx
Argenx is not just focusing on today's needs; it is on a mission to revolutionize the treatment landscape for severe autoimmune diseases. Through collaborations with top academic researchers under its Immunology Innovation Program (IIP), the company translates cutting-edge science into effective treatments. Argenx is proud to have developed the first approved neonatal Fc receptor (FcRn) blocker, paving the way for breakthroughs in patient care across various regions, including the U.S., Europe, and Canada. The company is currently exploring efgartigimod in multiple serious autoimmune conditions and is in the process of advancing several experimental therapies.
Engagement in Social Media
To keep stakeholders informed and engaged, argenx actively communicates through various social media platforms. This strategy allows for up-to-date information dissemination and enhances community interaction. Investors and interested parties are encouraged to follow argenx’s updates through these channels, which not only provide news but also foster a sense of community among those interested in the company's mission.
Contact Information
For more inquiries about argenx, please reach out:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Frequently Asked Questions
What is the purpose of the investor conferences?
The investor conferences aim to foster engagement with investors, providing insights into the company’s strategies and advancements in immunology.
When is the Guggenheim Inaugural Healthcare Innovation Conference?
This conference is set for November 12, featuring a fireside chat at 2:30 p.m. ET in Boston.
How can I view the Guggenheim fireside chat?
A live webcast will be available on the argenx investors page for those who wish to participate online.
What are the capabilities of argenx?
Argenx specializes in developing innovative treatments for severe autoimmune diseases and has introduced the first approved neonatal Fc receptor blocker.
Who can I contact for more information?
For media-related inquiries, reach out to Ben Petok. For investor questions, Alexandra Roy and Lynn Elton are available for contact.
